HLN

HaleonB

NYSE / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

20%

Probability

Target price

$11.50

Analysis reference price unavailable

Analysis 2026-09-05 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$9.90

Analysis reference price unavailable

Analysis 2026-09-05 · RankAlpha Sentiment Codex

B-

Bear case

30%

Probability

Target price

$8.20

Analysis reference price unavailable

Analysis 2026-09-05 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-09-05

AI commentary

Fundamental tone is mixed: official H1 results showed strong margin, EPS, cash-flow, and market-share metrics, while revenue growth remained modest and FY guidance was unchanged. No reliable post-print price-reaction, analyst-revision, options, short-interest, employee, or social data were available; zero-valued fields are unavailable rather than neutral evidence.

RankAlpha Sentiment Codex - 2026-09-05

Open full AI memo

Evidence flagged

peer set is too generic or lacks enough direct operating comparators

Impact

tentative

Confidence

AI events

2026-07-30eventH1 2026 results showed margin and EPS strength, but growth remains modestMedium impact

H1 organic revenue growth was 2.6%, adjusted operating profit rose 8.2% at constant currency, adjusted margin expanded 120bp, adjusted EPS rose 12%, and FY 2026 guidance remained 3%-5% organic growth with high-single-digit adjusted operating-profit growth. [#PR-HLN-HY26-2026-07-30] ([official results](https://www.haleon.com/content/dam/haleon/corporate/documents/investors/results/hy-2026/hy26-statement.pdf.downloadasset.pdf))

2026-10-29catalystQ3 trading statement will test H2 accelerationMedium impact

Haleon’s scheduled 29 October trading statement should provide the next evidence on North American execution, innovation rollout, and recovery from respiratory-related softness. [#IR-HLN-EVENT-2026-10-29] ([official events calendar](https://www.haleon.com/investors/events-calendar))

2027-06-30catalystOral Health momentum and North America recoveryHigh impact

Oral Health grew 6.2% organically in Q2, led by Sensodyne and parodontax innovation, while North America improved to 3.1% growth from 1.0% in Q1. Sustained share gains and execution could support progress toward Haleon’s 4%-6% medium-term organic-growth ambition, but this remains execution-dependent. [#PR-HLN-HY26-2026-07-30]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-09-05 • Updated nightlySource: Internal modelMethodology